Arvinas - ARVN Stock Forecast, Price & News

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 5 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARVN shares.
View ARVN analyst ratings or view top-rated stocks.

18 analysts have issued 12-month price targets for Arvinas' stock. Their ARVN share price forecasts range from $27.00 to $95.00. On average, they expect the company's share price to reach $71.00 in the next twelve months. This suggests a possible upside of 102.3% from the stock's current price.
View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts.

Arvinas' stock was trading at $34.21 at the beginning of 2023. Since then, ARVN shares have increased by 2.6% and is now trading at $35.10.
View the best growth stocks for 2023 here.

Arvinas saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 4,660,000 shares, a decrease of 10.4% from the December 31st total of 5,200,000 shares. Based on an average daily volume of 553,300 shares, the short-interest ratio is presently 8.4 days. Approximately 10.2% of the company's shares are short sold.
View Arvinas' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our ARVN earnings forecast.

Arvinas, Inc. (NASDAQ:ARVN) posted its earnings results on Tuesday, November, 8th. The company reported ($1.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.98) by $0.26. The business had revenue of $30.30 million for the quarter, compared to analysts' expectations of $44.20 million. Arvinas had a negative trailing twelve-month return on equity of 36.12% and a negative net margin of 225.34%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

(ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Arvinas' stock is owned by a variety of institutional and retail investors. Top institutional investors include Emerald Advisers LLC (0.68%), Emerald Mutual Fund Advisers Trust (0.46%), Bank of Montreal Can (0.00%), State of New Jersey Common Pension Fund D (0.11%), Allspring Global Investments Holdings LLC (0.06%) and Joel Isaacson & Co. LLC (0.06%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon.
View institutional ownership trends.

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARVN stock can currently be purchased for approximately $35.10.

Arvinas (NASDAQ:ARVN) has a market capitalization of $1.87 billion and generates $46.70 million in revenue each year. The company earns $-191,000,000.00 in net income (profit) each year or ($4.76) on an earnings per share basis.

The company employs 280 workers across the globe.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com.